#CMSC16 – STRIVE Study Confirms Tysabri (Natalizumab) Safety in Early Relapsing-Remitting MS
Results from the STRIVE study support the safety of natalizumab (Tysabri) as a therapy for multiple sclerosis (MS) patients. The…
Articles by Patricia Inacio, PhD
#CMSC16 – Delayed-release Dimethyl Fumarate Benefits Newly Diagnosed MS Patients, According to Study
Newly diagnosed patients with relapsing-remitting multiple sclerosis (RRMS) show significant improvements when treated with delayed-release dimethyl fumarate (DMF), especially in terms…
#CMSC16 – MS Patients at Higher Risk for Loneliness, Study Shows
Researchers who looked at manifestations of loneliness found that the burden of loneliness is much higher in multiple sclerosis (MS) patients when…
#CMSC16 – Sexual Dysfunction in Hispanic MS Patients Exists with Other Issues, Study Shows
Sexual dysfunction correlates with depression and bladder dysfunction in Hispanic patients with multiple sclerosis (MS), according to the results of…
Variants of Gene Linked to MS, ANKRD55, Found in Immune Cells Associated with Disease
Researchers detected the expression of the gene ANKRD55 in immune cells, a gene that has been previously linked to multiple sclerosis (MS)…
MS and Young Adult-onset Hodgkin Lymphoma May Share Underlying Causes, Study Says
Previous studies suggested that multiple sclerosis (MS) and Hodgkin lymphoma might share underlying causes, including exposure to microorganisms in childhood,…
Key Pathway in Antibody B-Cell Production Identified, Important to Diseases Like MS
Scientists discovered two key players — TBK1 and ICOS — that control the effective production of antibodies and may offer new insights into…
Smoking Appears Linked to Brain Abnormalities in People with MS-related Disease, Study Suggests
A team of researchers suggested that cigarette smoking is associated with adverse effects to white matter in the brain, and reported that smoking may underlie the clinical course…
New Protein, Anoctamin 2, Identified as a Target of Autoantibody Production in MS
Researchers identified the chloride-channel protein anoctamin 2 (ANO2) as a new target for autoantibody production in multiple sclerosis (MS) patients.
Leptomeningeal Inflammation May Offer New Treatment Targets In Progressive Forms of MS
Researchers at Johns Hopkins University in Baltimore presented key findings today, Feb. 19, concerning the presence of contrast-enhancing lesions in later stages…
Results of New SPMS Study to Be Presented at ACTRIMS
At the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016, being held from Feb. 18–20 in New…
For MS Patients, New Guidelines for Controlling Rare Brain Infection Risk Under Tysabri Treatment
The European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC), responsible for assessing and monitoring safety issues for human medicines, completed a…
MS Campaign In UK Pushing for Broader Access to Medical Marijuana
A new campaign called “End our pain” is asking people to sign a petition calling on the U.K. to allow…
MS Neurologist Argues for Continued Use of Natalizumab as Disease Treatment
In a recent study of more than 1,200 patients with multiple sclerosis (MS), a research team reported that treatment with the…
MS Patients Under Natalizumab Treatment May Be at Risk of Rare Brain Infection
Multiple sclerosis (MS) patients treated with natalizumab have an increased risk of developing high levels of antibodies associated with a virus…
Vitamin D’s Influence on MS Target of New Study
A team of researchers recently discovered two novel multiple sclerosis (MS)-associated genes that are regulated by vitamin D levels. The…
MS Progression Halted Using Stem Cells Derived from Gum Tissue
A new source of stem cells, the mesenchymal stem cells (MSCs) isolated from the human periodontal ligament (hPDLSCs), offers a…
MS Study Questions Safety of Bacteria Commonly Used as Vaccine Adjuvant
In a recent study, a team of researchers argued that, contrary to what has been proposed, subclinical Bordetella pertussis colonization…
Potential Mechanism in MS Pathogenesis Seen in Study
Researchers found that a group of untreated patients with multiple sclerosis (MS) and patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)…
MS Active and Inactive Lesions Differ in Levels of Enzymes that Drive Glucose Metabolism
A research team recently showed that key enzymes of energy metabolism pathways are differentially expressed in active and inactive multiple…
MS May Be Triggered by the Death of Brain Cells
Researchers are proposing for a first time that multiple sclerosis (MS) is triggered by the death of a specific cell population within…
Potential MS Biomarker Seen in Adipose Tissue Secretion
In a new study titled “Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines,” researchers…
Some RRMS and SPMS Patients Share a Similar Gene Expression in Response to IFN Treatment
In a new study entitled “Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple…
Pomegranate Seed Oil May Be Therapy for MS Disease and Its Progression
In a recent study, researchers show how a natural antioxidant within pomegranate seeds is capable of inhibiting demyelination in a mouse…
Novel Protein Suppresses MS in Mouse Model, Inhibits Neuroinflammation in Spinal Cord
In a recent study entitled “Myelin oligodendrocyte glycoprotein (MOG35-55)-induced experimental autoimmune encephalomyelitis is ameliorated in interleukin-32 alpha…
Hypoxia-Measuring Technology in MS Could Be Potential Biomarker for Treatment Responses
In a new study entitled “Reduced cortical microvascular oxygenation in multiple sclerosis: a blinded, case-controlled study using a novel…
Could Remyelination Be Achieved in MS Using an Anti-Inflammatory Treatment?
In a recent study entitled “Promotion of Remyelination by Sulfasalazine in a Transgenic Zebrafish Model of Demyelination,” researchers investigated…
Potential MS Therapeutic Targets Found in Plasma Metabolites
In a new study entitled “Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal…
Novartis’ MS Drug Gilenya Prevents Activation of Key Immune Cells in Study
In a recent study entitled “Myeloid cells as target of fingolimod action in multiple sclerosis,” a team of scientists…
New Insights Into Immune Cells’ Behavior in MS May Lead To New Therapeutic Approach
In a recent study entitled “MicroRNA expression profiling of human blood monocyte subsets highlights functional differences,” a team of…